PMID- 31790314
OWN - NLM
STAT- MEDLINE
DCOM- 20200203
LR  - 20200203
IS  - 1744-7666 (Electronic)
IS  - 1465-6566 (Linking)
VI  - 21
IP  - 3
DP  - 2020 Feb
TI  - An evaluation of liraglutide including its efficacy and safety for the treatment 
      of obesity.
PG  - 275-285
LID - 10.1080/14656566.2019.1695779 [doi]
AB  - Introduction: The prevalence of obesity is increasing worldwide and associated 
      conditions, particularly type 2 diabetes mellitus (T2DM), also show increasing 
      prevalence. Lifestyle intervention should be the first line of management for 
      obesity but additional pharmacotherapy is often required and bariatric surgery is 
      appropriate in more severe cases. Drugs acting as glucagon-like peptide-1 
      receptor agonists (GLP-1RAs) developed for the management of T2DM reduce body 
      weight and liraglutide is the first GLP-1RA to be approved for the treatment of 
      obesity in patients with and without T2DM.Areas covered: In this review of 
      relevant published material, the authors summarize the pharmacokinetics, 
      pharmacodynamics, clinical efficacy and safety of liraglutide for the treatment 
      of obesity.Expert opinion: Liraglutide effectively reduces body weight and body 
      fat through mechanisms involving reduced appetite and lowered energy intake, 
      independent of its glucose-lowering effects. Like most of the other medications 
      currently available for obesity, liraglutide has some common adverse effects, 
      although generally not serious ones. Liraglutide has additional benefits in 
      reducing cardiovascular events in patients with T2DM but the cost and the need 
      for daily injections may limit its use in obesity. Newer GLP-1RAs, such as 
      semaglutide, or other drugs in development for obesity may have advantages over 
      liraglutide.
FAU - Lin, Chen-Hsiu
AU  - Lin CH
AD  - Division of Cardiology, Department of Internal Medicine, Taipei Medical 
      University, Taipei, Taiwan.
FAU - Shao, Li
AU  - Shao L
AD  - The VIP Department, Shanghai East Hospital, Tongji University School of Medicine, 
      Shanghai, China.
FAU - Zhang, Yu-Mei
AU  - Zhang YM
AD  - The VIP Department, Shanghai East Hospital, Tongji University School of Medicine, 
      Shanghai, China.
FAU - Tu, Yu-Ju
AU  - Tu YJ
AD  - The VIP Department, Shanghai East Hospital, Tongji University School of Medicine, 
      Shanghai, China.
FAU - Zhang, Yuzhen
AU  - Zhang Y
AUID- ORCID: 0000-0002-9570-1269
AD  - Research Center for Translational Medicine, Shanghai East Hospital Affiliated to 
      Tongji University School of Medicine, Shanghai, China.
FAU - Tomlinson, Brian
AU  - Tomlinson B
AUID- ORCID: 0000-0001-6717-5444
AD  - Research Center for Translational Medicine, Shanghai East Hospital Affiliated to 
      Tongji University School of Medicine, Shanghai, China.
AD  - Faculty of Medicine, Macau University of Science and Technology, Taipa, Macau.
FAU - Chan, Paul
AU  - Chan P
AD  - Division of Cardiology, Department of Internal Medicine, Wan Fang Hospital, 
      Taipei Medical University, Taipei City, Taiwan.
FAU - Liu, Zhongmin
AU  - Liu Z
AD  - Department of Cardiac Surgery, Shanghai East Hospital, Tongji University, 
      Shanghai, China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20191202
PL  - England
TA  - Expert Opin Pharmacother
JT  - Expert opinion on pharmacotherapy
JID - 100897346
RN  - 0 (Glucagon-Like Peptide-1 Receptor)
RN  - 0 (Hypoglycemic Agents)
RN  - 53AXN4NNHX (semaglutide)
RN  - 62340-29-8 (Glucagon-Like Peptides)
RN  - 839I73S42A (Liraglutide)
SB  - IM
MH  - Body Weight/drug effects
MH  - Diabetes Mellitus, Type 2/drug therapy
MH  - Glucagon-Like Peptide-1 Receptor/agonists
MH  - Glucagon-Like Peptides/therapeutic use
MH  - Humans
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Liraglutide/*therapeutic use
MH  - Obesity/*drug therapy
OTO - NOTNLM
OT  - GLP-1 receptor agonist
OT  - liraglutide
OT  - obesity
OT  - semaglutide
OT  - type 2 diabetes mellitus
EDAT- 2019/12/04 06:00
MHDA- 2020/02/06 06:00
CRDT- 2019/12/03 06:00
PHST- 2019/12/04 06:00 [pubmed]
PHST- 2020/02/06 06:00 [medline]
PHST- 2019/12/03 06:00 [entrez]
AID - 10.1080/14656566.2019.1695779 [doi]
PST - ppublish
SO  - Expert Opin Pharmacother. 2020 Feb;21(3):275-285. doi: 
      10.1080/14656566.2019.1695779. Epub 2019 Dec 2.